The Trump administration has moved to end funding for a broad swath of HIV vaccine research, saying current approaches are ...

U.S. President Donald Trump heads to Pittsburgh, Pennsylvania on Friday to headline a rally to celebrate Nippon Steel's ...

GILD stock jumps 21.1% YTD as HIV dominance, lenacapavir progress, and liver drug approval offset oncology pressures. However ...

Gilead Sciences is well-positioned to continue to strengthen its position as a leader in the HIV therapy market. Learn more ...

Shares of Gilead Sciences, Inc. (GILD) were in the spotlight on Friday morning after the company reportedly said that it ...

Gilead Sciences, Inc. GILD announced positive top-line results from yet another late-stage study on breast cancer drug, ...

Data from both studies showcased the superiority of twice-yearly injectable, lenacapavir, compared to once-daily oral Truvada and background HIV incidence rates, prompting Gilead to unblind the ...

The US regulator has started a priority review of the injectable formulation of HIV-1 capsid inhibitor lenacapavir, which also has breakthrough status, and is due to deliver a decision on the ...

May 29, 2025 — New HIV research shows that small changes in the virus affect how quickly or slowly it replicates and how easily it can reawaken in the body. These insights bring researchers ...

Physicians and their patients report that engagement in an HIV-based community rivals drug effectiveness in the ongoing efforts to curtail an epidemic. Confronting the HIV Epidemic: There's an App ...